While irinotecan monotherapy was able to completely block human MLL-rearranged ALL expansion in mice when treatment was initiated shortly after xenotransplantation, this may not represent a clinically relevant model, as patients present with full-blown leukemia at diagnosis. The gene discussed is KMT2A; the disease is acute lymphoblastic leukemia.